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Abstract
Background: Antibody-fluorophore conjugates are invaluable reagents used in contemporary molecular cell
biology for imaging, cell sorting and tracking intracellular events. However they suffer in some cases from batch to
batch variation, partial loss of binding and susceptibility to photo-bleaching. In theory, these issues can all be
addressed by using recombinant antibody fused directly to genetically encoded fluorescent reporters. However,
single-chain fragment variable domains linked by long flexible linkers are themselves prone to disassociation and
aggregation, and in some cases with isoelectric points incompatible with use in physiologically relevant milieu.
Here we describe a general approach that permits fully functional intracellular production of a range of coloured
fluorescent recombinant antibodies with optimally orientated VH/VL interfaces and isoelectric points compatible for
use in physiological solutions at pH 7.4 with a binding site to fluorophore stoichiometry of 1:1.
Results: Here we report the design, assembly, intracellular bacterial production and purification of a panel of novel
antibody fluorescent protein fusion constructs. The insertion of monomeric fluorescent protein derived from either
Discosoma or Aequorea in-between the variable regions of anti-p185HER2-ECD antibody 4D5-8 resulted in optimal VH/
VL interface interactions to create soluble coloured antibodies each with a single binding site, with isoelectric
points of 6.5- 6. The fluorescent antibodies used in cell staining studies with SK-BR-3 cells retained the fluorophore
properties and antibody specificity functions, whereas the conventional 4D5-8 single chain antibody with a
(Gly4Ser)3 linker precipitated at physiological pH 7.4.
Conclusions: This modular monomeric recombinant fluorescent antibody platform may be used to create a range
of recombinant coloured antibody molecules for quantitative in situ, in vivo and ex vivo imaging, cell sorting and
cell trafficking studies. Assembling the single chain antibody with monomeric fluorescent protein linker facilitates
optimal variable domain pairing and alters the isoelectric point of the recombinant 4D5-8 protein conferring
solubility at physiological pH 7.4. The efficient intracellular expression of these functional molecules opens up the
possibility of developing an alternative approach for tagging intracellular targets with fluorescent proteins for a
range of molecular cell biology imaging studies.
Background
Flow cytometry and molecular imaging [1,2] techniques
are used in a wide range of applications including the
isolation of stem cells to the earlier and more precise
diagnosis and prognosis in various human health condi-
tions (i.e., oncological, haematological, immunological,
neurological and cardiovascular disease). With the
sequencing and annotation of the human genome(s)
combined with the discovery of panels of disease asso-
ciated biomarkers the need for fast and reliable probes
that work in multiple formats (i.e., protein, tissue arrays
and cell sorting) are required. Immunofluorescent label-
ling methods with appropriate imaging instruments
offer a range of sensitive and quantitative approaches.
The key reagent in the immunofluorescent staining
method introduced by Coons [3] has been refined over
the past 70 years, it has two basic components, the
fluorophore and the antibody. The fluorophores in use
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today are either chemical entities requiring site specific
conjugation or genetically encoded molecules [4,5]. The
vast majority of antibodies in use in immunofluorescent
techniques today are still conventional animal derived
poly or monoclonal preparations. However, over the
past two decades advances in the application of recom-
binant DNA technology for creating and accessing
recombinant immunoglobulin Fab or single-chain frag-
ment variable (scFv) antibodies from hybridomas or
large combinatorial libraries [6-10] has led to a plethora
of genetically encoded antibody reagents. These in vitro
technologies for accessing recombinant scFv antibodies
have been extensively reviewed elsewhere [11]. Combin-
ing recombinant scFv and fluorescent proteins (FPs) for
the assembly of genetically encoded antibody-fluoro-
phore as a direct fusion for use in molecular imaging
has also been described [4,5,12-17]. Nonetheless, since
the initial articles describing the green fluorescent pro-
tein (GFP)-antibody fusion, the uptake of the technology
and the applications have been limited [5]. This may be
due to a number of factors. The early GFP cloned from
Aequorea, and Renilla forms dimers [18] and red fluor-
escent protein (DsRed) from Discosoma forms tetramers
[19], these properties greatly hindered the use of these
molecules to create monovalent fusion tags. Secondly
the emission spectrum of GFP was suboptimal for use
with tissues, cells and in combination with other routi-
nely used probes. Thirdly conventional scFv antibody
domains linked by long flexible linkers are themselves
prone to dissociation and aggregation [20,21], reducing
the specific activity and fourthly the requirement for
secretion of the recombinant antibodies into the oxidis-
ing periplasmic space permitting intra molecular disul-
fide bond formation significantly reduces the yield (0.1-
0.2 mg of antibody-GFP fusion/L bacterial culture) [22].
Alternative expression platforms such as mammalian
and insect cells have also been used to produce scFv-
GFP fusions [23-25], but at increased costs. Additionally
yeast cells have also been used to express and secrete
antibody-GFP fusions [16,26-29] with respectable recov-
ery of secreted GFP-scFv fusions (up to 5 mg/L). These
alternative expression modalities dealt with increasing
the recovery of the secreted recombinant molecules and
not the intrinsic stability of the antibody-GFP proteins.
The mutagenesis of DsRed first to create monomeric
red fluorescent protein and then further manipulation
resulted in the creation of an attractive fusion partner
with rapid maturation, useful optical (excitation/emis-
sion 584/607 nm) and physical (photo- and pH 5-11
stable) properties (mRFP1) [30]. The emission spectrum
of mRFP1 607 nm is distinct from other fluorophores
and provides for greater separation from cell and tissue
auto-fluorescence. Coloured derivatives based on the
mRFP1 template (mHoneydew to mPlum) further
extend the palette for a range of molecular cell biology
applications [31,32]. Additionally other candidate fluor-
escent proteins based on Aequorea victoria GFP with
varying physical characteristics, some of which are
monomeric have also been developed and reviewed else-
where [33]. Moreover at a molecular level in these
monomeric fluorescent protein the C- and N- termini of
the mature proteins are predicted to be approximately
25Å apart in the same spatial plane on the top of the b-
barrel structure (i.e., facing the same direction), hence
could bridge across such distances in molecular
assemblies.
The traditional scFv design is based on the known X-
ray structures of antibody Fab molecules, where the dis-
tance between the C- termini of the VH and the N-ter-
mini of the VL chains or C- termini of the VL and the
N-termini of the VH chains were determined to be
approximately 35Å [34,35]. This 35Å stretch has con-
ventionally been spanned using long flexible amino-
acids linkers based on (Glycine4Serine)n = 3-6, or the 1
st
b-stand of the CH1 domain [36,37] such linkers are
long enough to permit intra-molecular VH/VL interface
pairing, resulting in a functional binding site. However
they are also long and flexible enough to permit disso-
ciation of the VH/VL resulting in loss of binding and
facilitate aggregation and shorter linkers of 12 amino-
acids or less result in inter-molecular VH/VL pairing
leading to multimeric assemblies [38,39]. Also the vari-
able domains taken out of the context of an IgG or the
Fab fragment in some cases have an isoelectric point
(pI) that is incompatible with the physiological milieu.
The 4D5-8 scFv with a (Gly4Ser)3 linker that has been
extensively studied has a predicted pI of 8.0 and in phy-
siological buffers at pH7.4 the protein is insoluble. Ide-
ally what is required is a genetically encoded solution
for bridging the 35Å gap with a rigid structure that
allows VH/VL interface pairing resulting in monomeric
assembly limiting VH/VL dissociation and an overall pI
shift to a more favourable range. Since the FP carboxyl-
and amino- termini are 25Å apart, it was reasoned that
with minor modifications this distance could be
extended to 35Å in the same plane without impacting
on the fluorophore properties. Such a modified FP could
be docked between the VH/VL domains to provide an
alternative bridging molecule replacing the CH1 with
respect to the Fd chain and linking directly to the N-ter-
mini of the VL domain, yet holding the two variable
domains in the correct orientation and optimal distance
to mimic VH/VL interface pairing observed in the Fab
molecules [40]. Furthermore it was predicted that the
addition of mRFP1 between the variable domains would
shift the pI from 8.0 to 6.5 conferring solubility at
pH7.4. Finally a low cost expression platform that per-
mits the recovery of correctly folded immunoglobulin
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variable domains with correct disulfide bond formation
is desirable. This is not a trivial undertaking, the effi-
cient folding of proteins with multiple disulfide bonds in
the cytoplasm of most K12 derived Escherichia coli is
problematic under physiological conditions where the
formation of stable disulfide bonds is not favoured.
However in some mutant strains in which the reduction
of thioredoxins and glutathione is impaired, oxidised
functional proteins with multiple disulfide bonds can be
recovered [41]. Moreover correctly folded active Fab
antibody fragment have been recovered from E. coli Ori-
gami™ host that also have mutations in both the thiore-
doxin reductase (trxB) and glutathione reductase (gor)
genes and the production further enhanced via the co-
expression of molecular chaperones [42].
In this study the scFv based on 4D5-8 a humanised
antibody against p185HER-2-ECD (Trastuzumab, Hercep-
tin™), that is widely used in breast cancer immunother-
apy [43] was assembled initially with monomeric red
and subsequently with blue, cerulean and citrine fluores-
cent proteins (RFP, BFP, CER and CIT) as bridging
molecules. The resulting fluorescent antibody proteins
were expressed at high levels and recovered in func-
tional form from the bacterial cytoplasm of gor-/trxB-
Rosetta gami strain of E. coli. The 4D5-8 scFv is known
to be well folded, thermodynamically stable and has
been used in various applications to create fusions with
RNase [44] and a photosensitiser protein [45]. Here we
provide data to support RED-, BFP-, CER- and CIT-
antibody 4D5-8 to further extend the utility of recombi-
nant fluorescent proteins as novel bridging molecules
and present a panel of candidates for developing tests
for quantitatively detecting p185HER-2-ECD. The intracel-
lular expression, with correct folding and assembly of
the genetically encoded fluorescent antibody provides an
economical route for protein production and recovery.
Results
Molecular modelling
A rational approach was used in engineering of scFv
4D5-8 fusion with mRFP1 based on the x-ray crystal
structure of 4D5-8 Fab (PDB 1N8Z) [46] and the mod-
elled structure of mRFP1 based on the DsRed dimer
(PDB 1G7K[19]. We proposed the fusion of the C-ter-
mini of 4D5-8 VH chain to the N-termini of mRFP1
and the 4D5-8 N-termini of VL to the C-termini of
mRFP1 with the addition of optimal linkers separating
both protein functions yet preserving the correct spa-
tial dimensions for VH/VL interaction and fluorophore
activity (Figure 1). With the addition of five amino
acid (Gly4Ser) linkers to both ends between the immu-
noglobulin domains and the mRFP1 the distance
between the N- and C- termini can readily be
extended to 35Å apart in the same orientation. The
predicted structure shows that the mRFP1 would not
interfere with the scFv binding site which is fully avail-
able to contact the target ligand. This precise spatial
geometry would permit the docking of mRFP1 or any
of its derivatives between the antibody VH/VL or VL/
VH chains resulting in functional scFv fluorophore
fusions. The predicted pI based on the translated
sequence were 6.5 (4D5-8RFP), 6.43 (4D5-8BFP), 6.16
(4D5-8CER) and 6.29 (4D5-8CIT).
Construction of the p4D5-8 scFv 15 linker, p4D5-8 scFv 5
linker, and p4D5-8RFP vectors
A NcoI/NotI fragment encoding the 4D5-8 scFv VH-VL
orientation with a fifteen or five amino acid (Gly4Ser)n =
3 or 1 linker incorporating an in-frame BamHI (GGA
TCC) restriction site (encoding amino acids Gly Ser)
(Figure 2A, B) were directionally inserted into a modi-
fied pET32a vector. Modified mRFP (Figure 2C) with
similar linkers on both ends was inserted into the scFv
BamHI site (Figure 2D). The pET32a expression vector
Figure 1 A 3D model of the genetically encoded fluorescent
antibody. Molecular model (ribbon representation) of the
Herceptin™ antigen-binding fragment (Fv) and human Her2 (PDB
1N8Z) complexed with of mRFP1 based on DsRed (PDB 1G7K). A
portion of Her2 is shown in orange, VH chain of 4D5-8 in green,
mRFP1 in red and VL chain of 4D5-8 antibody in navy blue.
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was initially modified to remove the NdeI-NotI fragment
and replaced with a NcoI-NotI cloning site resulting in
an in-frame C terminal hexa-histidine tag (Figure 3).
The corresponding 4D5-8BFP, CER and CIT antibodies
were assembled in a similar manner.
Protein expression and purification
The 52 kDa protein (4D5-8RFP) was expressed in
Rosetta gami B(DE3) E. coli in 200 mL culture in a 1
L shake flasks. During the expression phase the bac-
teria attained a distinct red pigmentation. The protein
was initially enriched from cell lysate by immobilised
metal ion chromatography (IMAC) and fractions ana-
lysed by SDS-PAGE (Figure 4A), prior to analysis by
gel filtration chromatography. On SDS-PAGE the
upper band corresponds to the intact protein, recov-
ered from the cell lysis and the lower bands are the
breakdown products due heat induced proteolysis at
the chromophore site which has also been reported by
others [45]. The proteolysis occurs upon sample pre-
paration for SDS-PAGE. The 4D5-8RFP elution profile
was compared with a panel of standard proteins con-
firming the monomeric state (Figure 4B). The fraction
with the red pigmentation corresponded with eluted
fractions 32-37.
A final yield of the 4D5-8RFP was 5 mg/L of bacterial
culture. The 4D5-8BFP, CER and CIT were prepared
following the same protocol. The 4D5-8 scFv with a 15
amino acid linker was expressed in a similar manner
and purified on IMAC alone. The IMAC affinity
enriched 4D5-8 scFv protein precipitated upon elution.
Surface Plasmon Resonanace (SPR)
To characterise the binding activity of 4D5-8RFP we
used SPR as previously reported [40] and compared the
values obtained with those reported in the literature
(Figure 5 SPR). The 4D5-8 scFv with a (G4S)3 linker was
not stable in the buffer conditions used for the SPR
study at pH7.4 and was not further characterised. The
calculated KD for 4D5-8RFP binding to p185
HER-2-ECD
was 2.2 ± 0.8 nM [40].
Fluorescence Analysis
To further characterise the binding activity of two of the
constructs 4D5-8RFP and 4D5-8CIT we used immuno-
fluorescent cell staining as shown in Figure 6. Purified
4D5-8RFP recognised SK-BR-3 breast carcinoma cells
that are characterised by high expression levels of
p185HER-2 and are used as a +++ positive control in the
FDA approved HercepTest (DAKO) and did not recog-
nise the MDA-MD-231 cancer cells which do not
express p185HER-2 and are used as a negative control in
the same test [47]. Immunofluorescent staining of SK-
BR-3 breast cancer cells revealed that purified 4D5-
8RFP effectively accumulates on the surface of these
Figure 2 The assembly of the 4D5 recombinant antibody
constructs. (A) 4D5-8 scFv 15 amino acid linker. The mature protein
begins with VH chain, followed by a (Gly4Ser)3 linker, VLchain. The
sites used to directionally insert the in-frame scFv encoding
sequence are underlined (NcoI-NotI). (B) 4D5-8 scFv 5 amino acid
linker. The mature protein begins with VH chain, followed by a
(Gly4Ser), VL chain. The sites used to directionally insert the in-frame
scFv encoding sequence are underlined (NcoI-NotI). The linker
terminal Gly Ser underlined is encoded by an in frame BamHI site.
(C) Modified mRFP1. The mRFP1 sequence is flanked by two in-
frame BamHI sites underlined. The alternative BFP, CER and CIT
encoding sequences were modified in a similar manner. (D) 4D5-
8RFP. The modified mRFP1 (C) was inserted into 4D5-8 scFv 5
amino acid linker construct (B) at the BamHI site.
Figure 3 Plasmid maps of p4D5-8RFP used to clone and
express red fluorescent antibody. The expression cassette has a
T7 promoter region, a lac operator, a ribosome-binding site
followed by a cloning region with NcoI and NotI restriction sites for
the insertion of the DNA sequences. At the end, there is a T7
termination sequence to restrict translation to the expression of
RNA for the recombinant protein. The vector also has the ampicillin
resistance gene, ColE1 pBR322 origin of replication and lacI
repressor gene.
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cells after 30 minute incubation at ambient temperature.
TO-PRO3 was used as a nuclear dye and phalloidin-
FITC as an actin label. The 4D5-8mCIT used to stain
SK-BR-3 breast carcinoma cells also had a similar sur-
face labelling to 4D5-8mRFP. The 4D5-8mCIT and
phalloidin-FITC images were not merged since the
emission spectra were similar (indistinguishable). The
BFP and CER fusions were not further evaluated by
fluorescence microscopy due to lack of suitable filter
sets. Furthermore excitation and emission analysis of
purified 4D5-8BFP, 4D5-8-CER and 4D5-8CIT proteins
were determined and shown to be intact in the antibody
format (Figure 7).
Discussion
Genetically encoded fluorescent antibody technology
described more than a decade ago[4], has not been
widely adopted to create fluorescent probes. In part this
has been due to properties of the available fluorophores.
The problems with the fluorophores have largely been
overcome by the creation of monomeric fluorescent
proteins [30] and the creation of more desirable spectral
properties [31-33], leading to widespread use in molecu-
lar cell and developmental biology applications. However
the recombinant antibody applications in particular the
scFv’s have presented with stability, solubility and secre-
tion issues. The long peptides in the scFv that link the
VH/VL together also permit domain disassociation and
aggregation [21]. Secondly, the pI of the mature protein
is also important, in particular if the intended use is at
physiological pH 7.4. Finally, scFv secretion into the
bacterial periplasmic space varies considerably, impact-
ing on the yields of functional material. Nature has pro-
vided the solutions for the problem of VH/VL pairing
stabilisation and solubility. In conventional antibodies
the CH1 and the constant light chain orientate and hold
the VH and VL in place for optimal interface pairing.
Thus an approach that could conserve the Fab like VH/
VL pairing and permit fusion with a fluorescent protein,
with a pI compatible with physiological pH and could
be assembled in the cytoplasm of the cell would be
ideal. Inserting the FP between the VH and VL holds the
domains in close proximity similar to that observed in
Fab molecules. Secondly the FP domain fusion shifts the
pI, and in the case of 4D5-8, it now becomes soluble at
pH7.4. Both Fab and scFv have been produced in E. coli
carrying mutations in the thioredoxin reductase (trxB)
and/or glutathione oxidoreductase (gor) genes [41,42].
Providing an oxidising environment within the cyto-
plasm facilitates the formation of disulfide bonds and
the production of functional proteins and is not depen-
dent on a secretion pathway.
The 4D5-8FP’s have the following characteristics; they
are readily expressed and isolated from gor-/trxB- E. coli
Figure 4 Purification and characterization of the 4D5-8RFP
recombinant protein. (A) SDS-PAGE and Coomassie stained gel of
4D5-8RFP: molecular markers (Lane 1), uninduced sample (Lane 2),
IPTG induced sample (Lane 3), soluble fraction (Lane 4), flow-
through Ni2+-nitrilotriacetic acid column (Lane 5), wash fraction
(Lane 6), elution fractions using 500 mM imidazole (Lanes 7-10). (B)
Gel filtration chromatography of standards proteins (peaks 1-4) and
Ni2+-nitrilotriacetic acid enriched 4D5-8RFP protein using Sephadex
G 200 gel bead column calibrated with sweet potato b-amylase 200
kDa, bovine serum albumin 66 kDa, bovine erythrocyte carbonic
anhydrase 29 kDa and horse heart cytochrome c 12.4 kDa protein
standards (Sigma-Aldrich).
Figure 5 Surface plasmon resonance analysis of purified 4D5-
8RFP binding to recombinant p185HER2-ECD antigen
(SinoBiological Inc, Beijing, China).
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cytoplasm in a soluble form, monomeric, with a molecu-
lar weight similar to the Fab fragment (kDa~51-52), the
fluorophore activity remains unaltered and retain speci-
ficity of the parental antibody. At physiological pH7.4
the 4D5-8RFP with a predicted pI of 6.5 and charge -3
is soluble whereas the scFv 4D5-8 with (Gly4Ser)3 linker
with a pI of 8.0 and zero charge was observed to
precipitate. This has been observed by others working
with scFv 4D5 and resolved by using 2-(N-morpholino)
ethanesulfonic acid (MES) buffers at pH6.0 in the purifi-
cation process [48]. These 4D5-8FP molecules may be
used for the development of a diagnostic test for Her2
positive cells in biopsy samples by immunohistochemis-
try or possibly for enriching and detecting circulating
cancer cells by FACs. Moreover, since the palette of
monomeric fluorescent proteins all have the same basic
conserved b-barrel architecture as mRFP1 used in this
study, it was reasoned that the fluorophore could be
readily exchanged for additional coloured proteins that
have similar 11 b-sheet barrel-like structures [49]. We
also constructed 4D5-8 with fluorescent bridge proteins
based on the monomeric BFP, mCerulean and mCitrine
to produce blue, green and yellow antibodies. The
recently described monomeric reversibly switchable
enhanced green fluorescent protein (rsEGFP)[50,51] or
the photoswitchable orange-to-far-red fluorescent pro-
tein (PSmOrange) [52] could also be used in this plat-
form. Using this modular technology it should be
possible to create panels of antibodies with desired opti-
cal properties against a range of targets. The combina-
tion of different antibody specificities each with a
distinct colour opens up the possibility of integrated
Figure 6 Detection of 4D5-8RFP binding to p185HER-2 -overexpressing SK-BR-3 and non-expressing MDA-MD-231 cells by confocal
microscopy. Cells incubated with nuclear stain TO-PRO3, actin label Phalloidin-FITC conjugate and 4D5-mRFP. SK-BR-3 cells were also incubated
with TO-PRO3 and 4D5-mCIT.
Figure 7 Spectrophotometric determination of 1 mg/mL of
4D5-8 fluorescent proteins, RFP, CER, CIT and BFP.
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quantitative antibody mediated multiplexed fluorescence
analysis. Another potential application is in targeted
photoablation of cells, p185HER-2-ECD expressing cancer
cells have been targeted using 4D5 scFv fused to the N-
termini of KillerRed (dimeric) reporter [45]. Upon light
irradiation in oxygen rich environment the KillerRed
produces highly reactive oxygen species (ROS) which
oxidised molecules in close proximity resulting in
p185HER-2-ECD expressing cancer cell damage and death
[45]. These properties have also been assigned to other
fluorescent proteins and it has been experimentally con-
firmed that during formation of the chromophore one
molecule of H2O2 is generated for each molecule of
fluorescent protein [53]. The 4D5-8RFP and the other
fluorescent constructs described also generates ROS
upon exposure to excitation light in the presence of
oxygen, thus may also have potential in targeted cell
ablation. The far-red spectrum of mRFP1 and the
PSmOrange [52] which have a greater tissue penetration
may allow targeted use in in vivo imaging in small ani-
mals [54]. Previously we had reported similar mRFP1
constructs based on anti-sialyl-Tn and anti-sialylated
Lewis (Le)a antibodies B72.3 [55] and CA19.9 [56]
respectively. The products were isolated from the peri-
plasm of E. coli (yield ~1 mg/L) and shown to be func-
tional [40], thus demonstrating that the approach is not
restricted to a single VH/VL combination. Here we
extend the study to demonstrate the flexibility of the
approach in accommodating a range of different
coloured monomeric fluorescent proteins as linkers in
combination with anti-Her2 scFv 4D5-8 and high level
intracellular expression. The intracellular expression of
these affinity fluorescent probes in a range of cell types
may permit the directed tagging of intracellular targets
with fluorescent proteins for a range of molecular cell
biology imaging studies currently not possible via direct
fluorescent protein fusions.
Conclusions
Here we demonstrate cytoplasmic expression of func-
tional single chain Fv antibodies using a range of geneti-
cally encoded fluorophores to link the variable domains.
These constructs could be expressed in the bacterial
cytoplasm and readily recovered as functional molecules
that retained binding and fluorescence properties with-
out recourse to in vitro refolding. This platform may
also be applied to other existing mAbs to create the
next generation of diagnostic imaging, sorting and track-
ing molecules. The modular platform may also be used
to combine natural and synthetic immunoglobulin VH
and VL domains with libraries of fluorophores based on
monomeric RFP1 or GFP to create palettes of highly
specific coloured binding molecules that retain optimal
binding and spectral properties. Unlike conventional
scFv the incorporation of the mFP linker moieties into
the scFv antibody shifts the pI resulting in molecules
that are soluble at physiologically relevant pH7.4. The
Rosetta gami B(DE3) E. coli strain that is deficient in gor
and trxB, provides an efficient intracellular production
platform for these recombinant fluorescent antibodies.
Methods
Molecular modelling
X-ray structures of human Her2 with Herceptin™ anti-
body (PDB 1N8Z) and DsRed (PDB 1G7K) were down-
loaded from RCSB Protein data bank (http://www.pdb.
org/pdb/home/home.do). The mRFP1 model was gener-
ated by homology-modelling using server Swiss-Model.
MiFit program was used to obtain a molecular 3D
model of human Her2 with Herceptin™ Fv domains
and mRFP1. The 3D model of the proposed refined
structure 4D5-8RFP was generated using PyMol
software.
Construction of the expression p4D5-8mRFP vector
Genetic engineering manipulations, plasmid preparation,
cell culture, protein expression and cell lysis followed
the standard protocols.
Primers 4D5-8 15LINKF 5’-
CTCTGGCGGTGGCGGATCGGATATCCAGATGAC-
3’, 4D5-8 15LINKR 5’-CTGAACCGCCTCCACCCGAG-
GAGACGGTGACCAG-3’, PAKVLNOT 5’-
TCGAGTGCGGCCGCATCCGCGCGTTTGATCTC-
CACCTTGGTAC-3’ and PAKVHNCO 5’-TAGGC-
CATGGCCGAGGTTCAGCTGGTGGAG-3’ were used
in PCR amplification of the 4D5-8 variable regions to
construct 4D5-8 scFv. All primers were purchased from
Invitrogen. Plasmid pAK19 was provided by Dan Yan-
sura (Genentech) and pMT-RFP/pMT-BFP were pro-
vided by Ray St.Ledger (University of Maryland).
Restriction endonuclease NdeI, NcoI, NotI and BamHI,
T4 DNA ligase, CIP were purchased from New England
Biolabs (UK). The 4D5-8 scFv (5 amino acid linker) and
4D5-8 mRFP1 were transferred from pBAK14D5-8 and
pBAK14D5-8RFP[40] to the modified pET32a expres-
sion vector as NcoI-NotI fragments. The 4D5-8 scFv
with 15 amino acid linker was assembled from 4D5-8
scFv 5 amino acid linker template using PAKVHNCO/
4D5-8 15LINKR and 4D5-8 15LINKF/PAKVLNOT
respectively. The BFP was modified by PCR to incorpo-
rate in-frame flanking BamHI sites and the CER and
mCIT with inframe flanking BamHI sites were codon
optimised and synthesised (Epoch Biolabs Tx, USA),
and inserted into the BamHI site between the VH and
VL of 4D5-8 to generate 4D5-8BFP, -CER and -CIT. All
constructs were verified by DNA sequencing.
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Protein expression
To express the fluorescent protein antibody chimeras, in
the cytoplasm of Rosetta gami B(DE3) E. coli (EMD Che-
micals Inc., Gibbstown, NJ) cells were transformed with
the appropriate plasmid and plated onto LB agar supple-
mented with carbenicillin and chloramphenicol (100 μg/
mL and 34 μg/mL final concentration respectively). The
cells were allowed to grow at 37°C for 18 hours and the
following day, five fresh colonies were inoculated into 10
mL of LB media (with antibiotics) and grown at 37°C
(with shaking at 250 rpm) for 16 hours. Next day, 200
mL of pre-warmed LB media, prepared in 1 L conical
flasks (with antibiotics) were inoculated with 10 mL of
the overnight culture and grown at 37°C (with shaking at
250 rpm) until the optical density at 600 nm had reached
0.5, then the cells were placed on ice for 30 minutes and
isopropyl b-D-1- thiogalactopyranoside (IPTG) added
(final concentration 1 mM) to the cultures and the cells
were grown at 20°C for an additional 20 hours with shak-
ing at 250 rpm. Fifty mL aliquots of bacterial cultures
were pelleted by centrifugation for 20 minutes, 5,000
rpm at 4°C (using Sorvall SuperT 21 bench top centri-
fuge, with SL-250T rotor) the supernatant discarded and
the pellets retained for cytoplasmic protein extraction.
Protein purification and analysis
Proteins were prepared from the whole cell lysates, puri-
fied on 1 ml HisTrap HP Ni Sepharose™ column using
ÄKTAprime™ plus purification system (GE Healthcare)
and analyzed by 12% SDS-PAGE Tris-Glycine gels and
stained with Coomassie. The cells harvested from 50 mL
of culture were washed with 50 mL PBS, centrifuged, and
the pellet was resuspended in 5 mL lysis buffer (0.01 M
Tris HCl pH 8.0, containing 0.5 M NaCl, 10 mM imida-
zole and 0.1% v/v Triton X100) and sonicated on ice.
The lysate was then centrifuged at 22,000 × g for 30 min
at 4°C. The supernatant was used for the purification of
His-tagged proteins using immobilised metal affinity
chromatography (IMAC) and proteins were eluted with
500 mM imidazole. The metal affinity enriched proteins
were loaded onto Sephadex G200 gel filtration column
(GE Healthcare) pre-calibrated with sweet potato b-amy-
lase 200 kDa, bovine serum albumin 66 kDa, bovine ery-
throcyte carbonic anhydrase 29 kDa and horse heart
cytochrome c 12.4 kDa (Sigma-Aldrich) and run using
0.02 M Tris HCl pH 7.5 containing 0.15 M NaCl, with a
flow rate of 1 mL/min collecting 1 mL fractions.
Surface Plasmon Resonance
BiaCore: Affinity constants were determined using the
principal of surface plasmon resonance (SPR) with a
BiaCore 3000 (BiaCore Inc.). Recombinant extra-cellular
domain of Her2 (Met 1- Thr 652) of human ErbB2
(NP_004439.2) fused with the polyhistidine tag at the C-
terminus purchased from SinoBiological Inc (China) was
conjugated to two flow cells of the CM5 chip according
to manufacturer’s instructions. A range of the antibody
preparations (1.2, 2.41, 4.81, 9.63, 19.3 μM) in HBS buf-
fer at pH 7.4 (consisting of 10 mM 4-[2-hydroxyethyl]
piperazine-1-ethane-sulfonic acid, 0.15 M sodium chlor-
ide, 3 mM EDTA, 0.005% (v/v) polysorbate 20), were
introduced into the flowcells. As antibody bound to the
antigen of interest, there was a change in the SPR signal,
which was proportional to the amount of antibody
bound. After 500 seconds, antigen solution was replaced
with HBS buffer, and the dissociation of the antibody
from the antigen was then measured, again by the SPR
signal. Curve-fitting software provided by BiaCore gen-
erated estimates of the association and dissociation rates
from which affinities were calculated.
Stability at Physiological pH7.4
The recombinant 4D5-8 scFv 15 linker and the corre-
sponding 4D5-8 fluorescent proteins were purified fol-
lowing identical procedures. Whereas the 4D5-8RFP,
BFP, CER and CIT, all produced a soluble product, the
4D5-8 15 linker scFv precipitated upon elution from the
nickel affinity resin at pH7.4.
Fluorescence Analysis
The SK-BR-3 and MDA-MB-231 cell lines were main-
tained in RPMI medium 1640, supplemented with 10%
FCS, 2 mM L-glutamine and 50 mg/L streptomycin, 50
UI/ml penicillin in culture flasks. For immunofluores-
cent analysis experiments, cells were plated on glass
cover slips, pre-treated with 100% FCS for 30 mins, at
density of 4 × 103 cells per well and cultured overnight
at 37°C in a 5% CO2 atmosphere. Cells were fixed in
0.2% paraformaldehyde in PBS for 5 min, washed with
PBS 3×, treated with 0.1% Triton-X 100 in PBS for 5
min, washed as before, incubated with TO-PRO3 (Invi-
trogen) nuclear stain (blue), FITC-labelled phalloidin
(green) and 4D5-8RFP(red) (10 μg/ml) or with TO-
PRO3 and 4D5-8CIT (yellow), (10 μg/ml), for 30 min,
washed as before and analyzed using confocal fluores-
cence microscope Leica TCS SP2 50.
The purified 4D5-8 fluorescent proteins were analysed
to determine the excitation and emission spectra using
1 mg/mL protein in 0.02 M Tris HCl pH 7.5 containing
0.15 M NaCl on SpectraMAX Gemini EM fluorescence
microplate reader with Gemini EM software (Molecular
Devices, UK) using Optiplex 96 F microtitre plates (Per-
kin Elmer, UK).
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